Header Logo

AMAN U BUZDAR

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address7007 Bertner Avenue
Houston TX 77054-3403
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889. PMID: 35507014; PMCID: PMC9250637.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Ingle JN, Kalari KR, Barman P, Shepherd LE, Ellis MJ, Goss PE, Buzdar AU, Robson ME, Cairns J, Carlson EE, Eyman Casey A, Hoskin TL, Goodnature BA, Haddad TC, Goetz MP, Weinshilboum RM, Wang L. Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenet Genomics. 2021 01; 31(1):1-9. PMID: 32649577; PMCID: PMC7655717.
      Citations:    Fields:    Translation:Humans
    3. Cairns J, Ingle JN, Dudenkov TM, Kalari KR, Carlson EE, Na J, Buzdar AU, Robson ME, Ellis MJ, Goss PE, Shepherd LE, Goodnature B, Goetz MP, Weinshilboum RM, Li H, Bari MG, Wang L. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. JCI Insight. 2020 08 20; 5(16). PMID: 32701512; PMCID: PMC7455128.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    4. Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. Clin Pharmacol Ther. 2019 07; 106(1):219-227. PMID: 30648747; PMCID: PMC6612579.
      Citations: 3     Fields:    Translation:HumansCells
    5. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):45-50. PMID: 30193295; PMCID: PMC6331049.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    6. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306. PMID: 29374384.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    7. Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017 05 01; 28(5):1070-1077. PMID: 28453704; PMCID: PMC5790063.
      Citations: 29     Fields:    Translation:Humans
    8. Dudenkov TM, Ingle JN, Buzdar AU, Robson ME, Kubo M, Ibrahim-Zada I, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Barman P, Goetz MP, Northfelt DW, Moreno-Aspita A, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+?breast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Res Treat. 2017 Jul; 164(1):189-199. PMID: 28429243; PMCID: PMC5600471.
      Citations: 12     Fields:    Translation:Humans
    9. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421. PMID: 28275168; PMCID: PMC5354950.
      Citations: 13     Fields:    Translation:Humans
    10. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060. PMID: 28135148; PMCID: PMC5455352.
      Citations: 161     Fields:    Translation:Humans
    11. Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 2017 01; 161(2):363-373. PMID: 27866278; PMCID: PMC5226883.
      Citations: 3     Fields:    Translation:Humans
    12. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413. PMID: 27852698; PMCID: PMC5872813.
      Citations: 4     Fields:    Translation:Humans
    13. Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat. 2016 08; 159(1):109-18. PMID: 27449492; PMCID: PMC5011019.
      Citations: 15     Fields:    Translation:Humans
    14. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Moy B, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE, Martin M, Piccart-Gebhart M. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016 Mar; 56:85-92. PMID: 26829011.
      Citations: 3     Fields:    Translation:HumansCells
    15. Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A, Cuzick J. Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2763-70. PMID: 26078431.
      Citations: 15     Fields:    Translation:Humans
    16. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Moy B, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE, Martin M, Piccart-Gebhart M. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015 Apr 16; 17:56. PMID: 25888246; PMCID: PMC4423419.
      Citations: 16     Fields:    Translation:Humans
    17. Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Moy B, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE, TEACH Investigators, Martin M, Piccart-Gebhart M. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015 Apr; 51(6):685-96. PMID: 25752740.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    18. Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015 Jul; 99(Pt A):32-8. PMID: 25163006; PMCID: PMC4339673.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    19. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8. PMID: 24721590.
      Citations: 38     Fields:    Translation:Humans
    20. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11. PMID: 24562447; PMCID: PMC3999801.
      Citations: 62     Fields:    Translation:Humans
    21. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK, American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1317-25. PMID: 24239210; PMCID: PMC4176878.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    22. Buzdar AU. Meta-analysis: selective estrogen-receptor modulators reduce breast cancer incidence. Ann Intern Med. 2013 Sep 17; 159(6):JC9. PMID: 24042392.
      Citations:    Fields:    Translation:Humans
    23. Buzdar AU. Combination endocrine treatments unproven in breast cancer. Lancet Oncol. 2013 Sep; 14(10):917-8. PMID: 23902873.
      Citations:    Fields:    Translation:Humans
    24. Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat. 2013 Jul; 140(2):253-62. PMID: 23852223.
      Citations: 9     Fields:    Translation:Humans
    25. Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet. 2013 Jun 15; 381(9883):2077-8. PMID: 23769223.
      Citations: 1     Fields:    Translation:Humans
    26. Kelly CM, Buzdar AU. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer. Drugs. 2013 May; 73(6):505-15. PMID: 23605692.
      Citations: 7     Fields:    Translation:HumansAnimals
    27. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004. PMID: 23562929; PMCID: PMC3718505.
      Citations: 22     Fields:    Translation:Humans
    28. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol. 2013 Apr; 27(4):657-70. PMID: 23518928; PMCID: PMC3607698.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    29. Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN. Mammographic breast density response to aromatase inhibition. Clin Cancer Res. 2013 Apr 15; 19(8):2144-53. PMID: 23468058; PMCID: PMC3630282.
      Citations: 17     Fields:    Translation:Humans
    30. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, TEACH investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Jan; 14(1):88-96. PMID: 23234763.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    31. Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA. Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51. PMID: 22927527.
      Citations: 2     Fields:    Translation:Humans
    32. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5. PMID: 22331946.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    33. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012 Jun; 23(6):1378-86. PMID: 22317766; PMCID: PMC6267865.
      Citations: 22     Fields:    Translation:Humans
    34. Kelly CM, Buzdar AU. Aromatase inhibitors in premenopausal breast cancer. Lancet Oncol. 2012 Apr; 13(4):320-1. PMID: 22265695.
      Citations:    Fields:    Translation:Humans
    35. Ewer MS, Yang M, Buzdar AU. Screening for cardiac risk before anthracycline administration: what are the real benefits? Clin Breast Cancer. 2012 Feb; 12(1):1-3. PMID: 22130035.
      Citations:    Fields:    Translation:Humans
    36. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82. PMID: 22102688.
      Citations:    Fields:    Translation:Humans
    37. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61. PMID: 22084362; PMCID: PMC3236648.
      Citations: 33     Fields:    Translation:Humans
    38. Buzdar A, Vogel C, Schwartzberg L, Garin A, Perez A, Ingle J, Houghton M, Zergebel C, Kimball B. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer. 2012 Jul 01; 118(13):3244-53. PMID: 22045595.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    39. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, Buzdar A, Foxhall L, Hui D, Summers B, Rodriguez A, Dubois R, Shine KI. Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer. 2012 May 15; 118(10):2571-82. PMID: 22045610; PMCID: PMC3272132.
      Citations: 23     Fields:    Translation:Humans
    40. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783; PMCID: PMC3233286.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    41. Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol. 2011 Nov 10; 29(32):4266-72. PMID: 21990403.
      Citations: 17     Fields:    Translation:Humans
    42. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4273-8. PMID: 21990413.
      Citations: 251     Fields:    Translation:Humans
    43. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012 May 15; 118(10):2603-14. PMID: 22370716; PMCID: PMC3864019.
      Citations: 117     Fields:    Translation:Humans
    44. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93. PMID: 21953213; PMCID: PMC3274632.
      Citations: 21     Fields:    Translation:Humans
    45. Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Rittweger K, Miles DW, O'Shaughnessy J, Tjulandin S, NO16853 trial group, Hoersch S. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol. 2012 Mar; 23(3):589-597. PMID: 21633047.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    46. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat. 2011 Jul; 128(2):421-7. PMID: 21553292.
      Citations: 5     Fields:    Translation:Humans
    47. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62. PMID: 21482989; PMCID: PMC3107758.
      Citations: 35     Fields:    Translation:Humans
    48. Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J. Predictive algorithms for adjuvant therapy: TransATAC. Steroids. 2011 Jul; 76(8):777-80. PMID: 21470560.
      Citations: 9     Fields:    Translation:Humans
    49. Buzdar AU. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream. Lancet Oncol. 2011 Apr; 12(4):316-8. PMID: 21429798.
      Citations:    Fields:    Translation:Humans
    50. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9. PMID: 21209588; PMCID: PMC4331097.
      Citations: 13     Fields:    Translation:Humans
    51. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer. 2011 Jul 15; 117(14):3268-75. PMID: 21264831.
      Citations: 4     Fields:    Translation:Humans
    52. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec; 11(12):1135-41. PMID: 21087898.
      Citations: 294     Fields:    Translation:HumansCTClinical Trials
    53. Kelly CM, Buzdar AU. Anastrozole. Expert Opin Drug Saf. 2010 Nov; 9(6):995-1003. PMID: 20923259.
      Citations: 7     Fields:    Translation:Humans
    54. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Buzdar AU, Martin PM, Kobayashi R, Pusztai L, Andr? F. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics. 2010 Oct; 10(19):3525-32. PMID: 20827732.
      Citations: 7     Fields:    Translation:Humans
    55. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47. PMID: 20740500; PMCID: PMC2997136.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    56. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010 Jul 15; 116(14):3348-56. PMID: 20564075.
      Citations: 166     Fields:    Translation:HumansCTClinical Trials
    57. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9. PMID: 20564395; PMCID: PMC4361091.
      Citations: 44     Fields:    Translation:Humans
    58. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010 Apr 15; 70(8):3278-86. PMID: 20354183; PMCID: PMC2855746.
      Citations: 28     Fields:    Translation:Humans
    59. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010 Apr 10; 28(11):1829-34. PMID: 20212256.
      Citations: 258     Fields:    Translation:Humans
    60. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010 Feb 15; 116(4):814-21. PMID: 20052721; PMCID: PMC3806193.
      Citations: 6     Fields:    Translation:Humans
    61. Kelly CM, Buzdar AU. Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial. Expert Opin Pharmacother. 2010 Feb; 11(3):489-92. PMID: 20053139.
      Citations: 2     Fields:    Translation:CTClinical Trials
    62. Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, Fehrenbacher L, Geyer CE, Mamounas EP, Wolmark N, Robidoux A. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer. 2010 Feb; 10(1):81-6. PMID: 20133263.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    63. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010 Jan 01; 70(1):319-28. PMID: 20048079; PMCID: PMC2804935.
      Citations: 43     Fields:    Translation:Humans
    64. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol. 2009 Dec; 10(12):1179-87. PMID: 19959074.
      Citations: 40     Fields:    Translation:HumansAnimals
    65. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010 Jan 20; 28(3):509-18. PMID: 19949017.
      Citations: 260     Fields:    Translation:Humans
    66. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan 01; 28(1):92-8. PMID: 19933921; PMCID: PMC2799236.
      Citations: 259     Fields:    Translation:Humans
    67. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009 Dec 01; 15(23):7381-8. PMID: 19920100; PMCID: PMC2788123.
      Citations: 121     Fields:    Translation:HumansCells
    68. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain. 2009 Nov; 10(11):1146-50. PMID: 19595634; PMCID: PMC2783933.
      Citations: 36     Fields:    Translation:Humans
    69. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Noguchi S, Verma S, Hadji P, Maass N, Robidoux A. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast. 2009 Aug; 18 Suppl 2:S1-11. PMID: 19712865.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    70. Buzdar AU. Medical oncology: Endocrine-therapy-related symptoms and breast cancer. Nat Rev Clin Oncol. 2009 Jun; 6(6):309-10. PMID: 19483735.
      Citations: 1     Fields:    Translation:Humans
    71. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 2009 Jun; 20(6):993-9. PMID: 19150946.
      Citations: 30     Fields:    Translation:HumansCells
    72. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008 Dec; 8(6):516-21. PMID: 19073507.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    73. Buzdar AU. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 2008 Sep; 44(9):679-92. PMID: 19137123.
      Citations: 5     Fields:    Translation:Humans
    74. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008 Sep 01; 26(25):4072-7. PMID: 18757321; PMCID: PMC6557586.
      Citations: 71     Fields:    Translation:Humans
    75. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008 Oct 20; 26(30):4891-8. PMID: 18725649; PMCID: PMC2736998.
      Citations: 76     Fields:    Translation:Humans
    76. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81. PMID: 18701468; PMCID: PMC4441792.
      Citations: 12     Fields:    Translation:Humans
    77. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists' Group. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008 Sep; 9(9):866-72. PMID: 18703382.
      Citations: 66     Fields:    Translation:Humans
    78. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83. PMID: 18695137; PMCID: PMC6592411.
      Citations: 148     Fields:    Translation:Humans
    79. Jackson LR, Cheung KL, Buzdar AU, Robertson JF. Arzoxifene: the evidence for its development in the management of breast cancer. Core Evid. 2008 Jul 31; 2(4):251-8. PMID: 21221190; PMCID: PMC3012444.
      Citations: 2     
    80. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol. 2008 Dec; 19(12):2020-5. PMID: 18667396; PMCID: PMC2733116.
      Citations: 13     Fields:    Translation:Humans
    81. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8. PMID: 18581139.
      Citations: 4     Fields:    Translation:Humans
    82. Mazouni C, Arun B, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L, Andr? F. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer. 2008 Jul 08; 99(1):68-71. PMID: 18560403; PMCID: PMC2453019.
      Citations: 13     Fields:    Translation:Humans
    83. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008 Apr 01; 26(10):1664-70. PMID: 18316794.
      Citations: 142     Fields:    Translation:HumansCTClinical Trials
    84. Buzdar AU. Clinical experience with epothilones in patients with breast cancer. Clin Breast Cancer. 2008 Mar; 8 Suppl 2:S71-8. PMID: 18637402.
      Citations: 3     Fields:    Translation:Humans
    85. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9. PMID: 18258991.
      Citations: 123     Fields:    Translation:Humans
    86. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 2008 Feb 01; 112(3 Suppl):700-709. PMID: 18072256.
      Citations: 16     Fields:    Translation:Humans
    87. Come SE, Buzdar AU, Ingle JN, Johnston SRD, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 01; 112(3 Suppl):673-678. PMID: 18072254.
      Citations: 2     Fields:    Translation:Humans
    88. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008 Mar 01; 26(7):1059-65. PMID: 18227529.
      Citations: 132     Fields:    Translation:Humans
    89. Boughey JC, Buzdar AU, Hunt KK. Recent advances in the hormonal treatment of breast cancer. Curr Probl Surg. 2008 Jan; 45(1):13-55. PMID: 18206436.
      Citations:    Fields:    Translation:Humans
    90. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 Jan; 9(1):45-53. PMID: 18083636.
      Citations: 310     Fields:    Translation:Humans
    91. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52. PMID: 18056680.
      Citations: 49     Fields:    Translation:Humans
    92. Buzdar AU. Preoperative chemotherapy treatment of breast cancer--a review. Cancer. 2007 Dec 01; 110(11):2394-407. PMID: 17941030.
      Citations: 24     Fields:    Translation:Humans
    93. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007 Dec; 18(12):1927-34. PMID: 17998286.
      Citations: 103     Fields:    Translation:Humans
    94. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol. 2007 Nov 01; 25(31):4967-73. PMID: 17971595.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    95. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 01; 110(7):1436-44. PMID: 17694554.
      Citations: 69     Fields:    Translation:Humans
    96. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer. 2007 Sep 15; 110(6):1195-200. PMID: 17647266.
      Citations: 12     Fields:    Translation:Humans
    97. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 01; 25(28):4414-22. PMID: 17785706.
      Citations: 450     Fields:    Translation:Humans
    98. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortob?gyi GN. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007 Aug; 12(8):904-12. PMID: 17766649.
      Citations: 48     Fields:    Translation:Humans
    99. Buzdar AU. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. J Clin Oncol. 2007 May 20; 25(15):2147-8; author reply 2148. PMID: 17513830.
      Citations:    Fields:    Translation:Humans
    100. Buzdar AU. Adjuvant chemotherapy for high-risk operable breast cancer. J Clin Oncol. 2007 May 01; 25(13):1642-4. PMID: 17404366.
      Citations: 3     Fields:    Translation:Humans
    101. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80. PMID: 17293601.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    102. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007 Feb 01; 109(3):496-501. PMID: 17149760.
      Citations: 15     Fields:    Translation:Humans
    103. Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res. 2007; 9(6):R87. PMID: 18086299; PMCID: PMC2246190.
      Citations: 14     Fields:    Translation:HumansCells
    104. Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J. 2007 Jan-Feb; 13(1):72-5. PMID: 17214797.
      Citations: 7     Fields:    Translation:Humans
    105. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33. PMID: 17200359.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    106. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov; 13(11):1443-9. PMID: 17028770.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    107. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54. PMID: 16862596.
      Citations: 10     Fields:    Translation:Humans
    108. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3):464-70. PMID: 16926572; PMCID: PMC1856540.
      Citations: 34     Fields:    Translation:Humans
    109. Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006 Sep; 40(9):1572-83. PMID: 16912252.
      Citations: 11     Fields:    Translation:Humans
    110. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Hortobagyi GN, Pusztai L, G?mez HL. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44. PMID: 16896004.
      Citations: 264     Fields:    Translation:Humans
    111. Buzdar AU, Guastalla JP, Nabholtz JM, Cuzick J. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer. 2006 Aug 01; 107(3):472-80. PMID: 16804925.
      Citations: 6     Fields:    Translation:Humans
    112. Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin. 2006 Aug; 22(8):1575-85. PMID: 16870082.
      Citations: 6     Fields:    Translation:Humans
    113. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006 Aug; 7(8):633-43. PMID: 16887480.
      Citations: 106     Fields:    Translation:Humans
    114. Buchholz TA, Strom EA, Oswald MJ, Perkins GH, Oh J, Domain D, Yu TK, Woodward WA, Tereffe W, Singletary SE, Thomas E, Buzdar AU, Hortobagyi GN, McNeese MD. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1155-60. PMID: 16750325.
      Citations: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    115. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer. 2006 Jun 01; 106(11):2327-36. PMID: 16639731.
      Citations: 10     Fields:    Translation:Humans
    116. Buzdar AU. Anastrozole for breast cancer: recent advances and ongoing challenges. Expert Rev Anticancer Ther. 2006 Jun; 6(6):839-48. PMID: 16761927.
      Citations:    Fields:    Translation:Humans
    117. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15; 106(10):2095-103. PMID: 16598749.
      Citations: 91     Fields:    Translation:Humans
    118. Buzdar AU. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2409-11. PMID: 16682721.
      Citations: 3     Fields:    Translation:Humans
    119. Buzdar AU. St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy. Ann Oncol. 2006 May; 17(5):878-9. PMID: 16638951.
      Citations:    Fields:    Translation:Humans
    120. Buzdar AU. Update on the management of inflammatory breast cancer. Clin Adv Hematol Oncol. 2006 May; 4(5):344-5. PMID: 16728943.
      Citations:    Fields:    Translation:Humans
    121. Chlebowski RT. Letrozole or tamoxifen in early breast cancer. N Engl J Med. 2006 Apr 06; 354(14):1528-30; author reply 1528-30. PMID: 16602149.
      Citations:    Fields:    Translation:Humans
    122. Buzdar AU, Baum M, Cuzick J. Letrozole or tamoxifen in early breast cancer. N Engl J Med. 2006 Apr 06; 354(14):1528-30; author reply 1528-30. PMID: 16598051.
      Citations:    Fields:    Translation:Humans
    123. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 01; 24(7):1037-44. PMID: 16505422.
      Citations: 190     Fields:    Translation:Humans
    124. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006 Mar 01; 106(5):1000-6. PMID: 16444747.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    125. Buzdar AU. Dietary modification and risk of breast cancer. JAMA. 2006 Feb 08; 295(6):691-2. PMID: 16467239.
      Citations:    Fields:    Translation:Humans
    126. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64. PMID: 16432360; PMCID: PMC1448900.
      Citations: 66     Fields:    Translation:Humans
    127. Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1019s-1023s. PMID: 16467119.
      Citations: 9     Fields:    Translation:Humans
    128. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s. PMID: 16467115.
      Citations: 2     Fields:    Translation:Humans
    129. Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s. PMID: 16467118.
      Citations: 29     Fields:    Translation:HumansCells
    130. Hilsenbeck SG, Osborne CK. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s. PMID: 16467123.
      Citations: 2     Fields:    Translation:Humans
    131. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'Hern R. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1024s-1030s. PMID: 16467120.
      Citations: 42     Fields:    Translation:Humans
    132. Ingle JN. Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1031s-1036s. PMID: 16467121.
      Citations: 6     Fields:    Translation:Humans
    133. Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1037s-1048s. PMID: 16467122.
      Citations: 4     Fields:    Translation:Humans
    134. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005 Dec 20; 23(36):9304-11. PMID: 16361629.
      Citations: 100     Fields:    Translation:Humans
    135. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y, Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17; 366(9503):2087-106. PMID: 16360786.
      Citations: 1274     Fields:    Translation:Humans
    136. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005 Dec 01; 104(11):2359-64. PMID: 16270318.
      Citations: 48     Fields:    Translation:Humans
    137. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9. PMID: 16293864.
      Citations: 82     Fields:    Translation:Humans
    138. Buzdar AU, Cuzick J. Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8544-6; author reply 8546-7. PMID: 16293888.
      Citations: 1     Fields:    Translation:Humans
    139. Yamaya H, Saeki M, Yoshida K, Shibata J, Yano S, Sato Y, Takao A, Shindo T, Buzdar AU, Nagayama S. Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor. Drug Metab Dispos. 2006 Feb; 34(2):331-8. PMID: 16299166.
      Citations:    Fields:    Translation:Animals
    140. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod. 2006 Feb; 21(2):545-53. PMID: 16210385.
      Citations: 8     Fields:    Translation:Humans
    141. Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Yonezawa JI, Tsuda M, Shindo T, Nagayama S, Buzdar AU. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. J Clin Pharm Ther. 2005 Oct; 30(5):459-70. PMID: 16164493.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    142. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 01; 23(28):7098-104. PMID: 16192593.
      Citations: 32     Fields:    Translation:Humans
    143. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005 Sep 15; 104(6):1158-71. PMID: 16047352.
      Citations: 19     Fields:    Translation:Humans
    144. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92. PMID: 16087943.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    145. Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V, Bermejo B. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer. 2005 Jul 15; 104(2):229-35. PMID: 15937910.
      Citations: 9     Fields:    Translation:Humans
    146. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005 Jun 15; 103(12):2466-72. PMID: 15852360.
      Citations: 25     Fields:    Translation:Humans
    147. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7. PMID: 15890574.
      Citations: 33     Fields:    Translation:Humans
    148. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85. PMID: 15738535.
      Citations: 311     Fields:    Translation:HumansCTClinical Trials
    149. Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol. 2005 Feb; 93(2-5):237-47. PMID: 15860266.
      Citations: 7     Fields:    Translation:Humans
    150. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):889s-99s. PMID: 15701883.
      Citations: 13     Fields:    Translation:HumansCells
    151. Ingle JN. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):900s-5s. PMID: 15701884.
      Citations: 9     Fields:    Translation:Humans
    152. L?nning PE. Exemestane for breast cancer prevention: a feasible strategy? Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):918s-24s. PMID: 15701887.
      Citations: 1     Fields:    Translation:Humans
    153. Anderson WF, Devesa SS. Breast carcinoma in men. Cancer. 2005 Jan 15; 103(2):432-3; author reply 433. PMID: 15578682.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    154. Buzdar AU. TAS-108: a novel steroidal antiestrogen. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):906s-8s. PMID: 15701885.
      Citations: 7     Fields:    Translation:Humans
    155. Yue W, Wang JP, Li Y, Bocchinfuso WP, Korach KS, Devanesan PD, Rogan E, Cavalieri E, Santen RJ. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):925s-30s. PMID: 15701888.
      Citations: 16     Fields:    Translation:HumansAnimals
    156. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS, L?nning PE. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s. PMID: 15701878.
      Citations:    Fields:    Translation:Humans
    157. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Buccholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005 Jan 01; 23(1):41-8. PMID: 15625359.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    158. Buzdar A, Macahilig C. How rapidly do oncologists respond to clinical trial data? Oncologist. 2005 Jan; 10(1):15-21. PMID: 15632249.
      Citations: 4     Fields:    Translation:Humans
    159. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005 Jan 01; 11(1):315-22. PMID: 15671561.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    160. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7; 365(9453):60-2. PMID: 15639680.
      Citations: 541     Fields:    Translation:Humans
    161. Buzdar AU. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis. 2005-2006; 24:107-17. PMID: 16917143.
      Citations: 3     Fields:    Translation:Humans
    162. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004 Dec 01; 22(23):4691-9. PMID: 15570071.
      Citations: 56     Fields:    Translation:Humans
    163. Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst. 2004 Nov 17; 96(22):1676-81. PMID: 15547180.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    164. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004 Oct 15; 101(8):1760-6. PMID: 15386311.
      Citations: 24     Fields:    Translation:Humans
    165. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13. PMID: 15378497.
      Citations: 7     Fields:    Translation:Humans
    166. Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer. 2004 Oct 01; 101(7):1482-9. PMID: 15378476.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    167. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6215-21. PMID: 15448010.
      Citations: 11     Fields:    Translation:HumansCells
    168. Buzdar AU. Current developments in hormonal therapy of breast cancer. Clin Breast Cancer. 2004 Sep; 5 Suppl 1:S4-5. PMID: 15347432.
      Citations:    Fields:    Translation:Humans
    169. Resetkova E, Gonzalez-Angulo AM, Sneige N, Mcdonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer. 2004 Sep 01; 101(5):913-7. PMID: 15329897.
      Citations: 4     Fields:    Translation:HumansCells
    170. Buzdar AU. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 2004 Sep; 40(9):751-64. PMID: 15538548.
      Citations: 3     Fields:    Translation:HumansAnimals
    171. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer. 2004 Sep; 11(3):391-406. PMID: 15369444.
      Citations: 17     Fields:    Translation:Humans
    172. Buzdar AU. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. Clin Breast Cancer. 2004 Sep; 5 Suppl 1:S6-S12. PMID: 15347433.
      Citations: 6     Fields:    Translation:Humans
    173. Blakely LJ, Buzdar A, Chang HY, Frye D, Theriault R, Valero V, Rivera E, Booser D, Kuritani J, Tsuda M. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5425-31. PMID: 15328180.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    174. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004 Aug 01; 101(3):466-75. PMID: 15274059.
      Citations: 106     Fields:    Translation:Humans
    175. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42. PMID: 15275718.
      Citations: 9     Fields:    Translation:Humans
    176. Buzdar AU. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol. 2004 Aug 01; 22(15):3199-200; author reply 3200-1. PMID: 15284276.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    177. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer. 2004 Jul 15; 101(2):258-63. PMID: 15241821.
      Citations: 11     Fields:    Translation:Humans
    178. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004 Jul 01; 101(1):51-7. PMID: 15221988.
      Citations: 233     Fields:    Translation:Humans
    179. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004 Jun 15; 22(12):2294-302. PMID: 15197190.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    180. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004 Jun 15; 100(12):2512-32. PMID: 15197792.
      Citations: 29     Fields:    
    181. Buzdar AU, Vergote I, Sainsbury R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J. 2004 May-Jun; 10(3):211-7. PMID: 15125747.
      Citations: 4     Fields:    Translation:Humans
    182. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45. PMID: 15093909.
      Citations: 14     Fields:    Translation:Humans
    183. Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Adjuvant use of anastrozole in breast cancer. J Clin Oncol. 2004 Apr 15; 22(8):1524-6; author reply 1526-7. PMID: 15084628.
      Citations: 1     Fields:    Translation:Humans
    184. Buzdar AU. Preoperative chemotherapy for breast cancer. Clin Adv Hematol Oncol. 2004 Apr; 2(4):212, 215. PMID: 16163183.
      Citations:    Fields:    Translation:Humans
    185. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer. 2004 Apr 01; 100(7):1365-73. PMID: 15042669.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    186. Buzdar AU. Letrozole in breast cancer. N Engl J Med. 2004 Feb 12; 350(7):727-30; author reply 727-30. PMID: 14960751.
      Citations: 1     Fields:    Translation:Humans
    187. Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004 Feb 01; 100(3):465-9. PMID: 14745861.
      Citations: 40     Fields:    Translation:Humans
    188. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004 Feb 01; 100(3):499-506. PMID: 14745865.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    189. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004 Feb; 4(6):415-9. PMID: 15023242.
      Citations: 19     Fields:    Translation:Humans
    190. Buzdar AU. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):355S-61S. PMID: 14734491.
      Citations: 6     Fields:    Translation:Humans
    191. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004 Jan 01; 100(1):44-52. PMID: 14692023.
      Citations: 151     Fields:    Translation:Humans
    192. Ellis MJ. Neoadjuvant endocrine therapy as a drug development strategy. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):391S-5S. PMID: 14734497.
      Citations: 3     Fields:    Translation:HumansCells
    193. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):327S-330S. PMID: 14734487.
      Citations: 1     Fields:    Translation:HumansCells
    194. Buzdar AU. Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar. Drugs. 2004; 64(16):1848-9. PMID: 15301566.
      Citations:    Fields:    Translation:Humans
    195. Buzdar AU. Hormonal therapy in early and advanced breast cancer. Breast J. 2004 Jan-Feb; 10 Suppl 1:S19-21. PMID: 14984485.
      Citations:    Fields:    Translation:Humans
    196. Cameron DA. Paclitaxel in early breast cancer: a viewpoint by David A. Cameron. Drugs. 2004; 64(16):1848-9. PMID: 15301567.
      Citations:    Fields:    Translation:Humans
    197. Simons WR, Jones D, Buzdar A. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther. 2003 Nov; 25(11):2972-87. PMID: 14693319.
      Citations: 4     Fields:    Translation:Humans
    198. Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J, Arimidex Study Group, Th?rlimann B. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer. 2003 Nov; 39(16):2310-7. PMID: 14556922.
      Citations: 11     Fields:    Translation:Humans
    199. Buzdar AU. Aromatase inhibitors in breast cancer therapy. Clin Breast Cancer. 2003 Nov; 4 Suppl 2:S84-8. PMID: 14667279.
      Citations: 3     Fields:    Translation:Humans
    200. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003 Nov 01; 98(9):1802-10. PMID: 14584060.
      Citations: 179     Fields:    Translation:HumansCTClinical Trials
    201. Baum M, Buzdar A, Howell A. ATAC trial did not report interim results. BMJ. 2003 Nov 01; 327(7422):1050. PMID: 14593064; PMCID: PMC261674.
      Citations:    Fields:    Translation:Humans
    202. Buzdar AU. Breast cancer in men. Oncology (Williston Park). 2003 Oct; 17(10):1361-4; discussion 1364, 1369-72. PMID: 14606362.
      Citations: 5     Fields:    Translation:Humans
    203. Buzdar AU. Role of anastrozole in adjuvant therapy for postmenopausal patients. Semin Oncol. 2003 Oct; 30(5 Suppl 16):21-9. PMID: 14613023.
      Citations: 1     Fields:    Translation:Humans
    204. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44. PMID: 12957243.
      Citations: 24     Fields:    Translation:Humans
    205. Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, Buzdar AU, Buchholz TA. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):327-35. PMID: 12957242.
      Citations: 13     Fields:    Translation:Humans
    206. Buzdar AU, Hortobagyi GN. Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. Cancer Treat Rev. 2003 Oct; 29(5):449-52. PMID: 12972364.
      Citations:    Fields:    Translation:Humans
    207. Buzdar AU, ATAC trialists' group. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. J Steroid Biochem Mol Biol. 2003 Sep; 86(3-5):399-403. PMID: 14623537.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    208. Baum M, Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am. 2003 Aug; 83(4):973-94. PMID: 12875605.
      Citations: 3     Fields:    Translation:Humans
    209. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Th?rlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer. 2003 Aug; 39(12):1684-9. PMID: 12888362.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    210. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38. PMID: 12872340.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    211. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71. PMID: 12784330.
      Citations: 48     Fields:    Translation:Humans
    212. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23. PMID: 12767083.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    213. Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP. A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J. 2003 May-Jun; 9(3):213-22. PMID: 12752630.
      Citations:    Fields:    Translation:Humans
    214. Montemurro F, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT, Rond?n G. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant. 2003 May; 9(5):330-40. PMID: 12766883.
      Citations: 2     Fields:    Translation:Humans
    215. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003 Apr 01; 97(7):1758-65. PMID: 12655533.
      Citations: 18     Fields:    Translation:Humans
    216. Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clin Breast Cancer. 2003 Apr; 4 Suppl 1:S42-8. PMID: 12756078.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    217. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14. PMID: 12637464.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    218. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003 Mar; 78(1):105-18. PMID: 12611463.
      Citations: 76     Fields:    Translation:Humans
    219. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003; 8(4):335-41. PMID: 12897330.
      Citations: 14     Fields:    Translation:Humans
    220. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):468S-72S. PMID: 12538502.
      Citations: 10     Fields:    Translation:Humans
    221. Cristofanilli M, Buzdar AU, Hortob?gyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003; 8(2):141-8. PMID: 12697939.
      Citations: 32     Fields:    Translation:Humans
    222. Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S. PMID: 12538498.
      Citations: 2     Fields:    Translation:Humans
    223. Buzdar AU. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Rev Anticancer Ther. 2002 Dec; 2(6):623-9. PMID: 12503208.
      Citations: 2     Fields:    Translation:Humans
    224. Gluck S. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Cancer. 2002 Dec 01; 95(11):2442-3; author reply 2443-4. PMID: 12436453.
      Citations: 2     Fields:    Translation:Humans
    225. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002 Nov 01; 95(9):2006-16. PMID: 12404296.
      Citations: 60     Fields:    Translation:Humans
    226. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8. PMID: 12429622.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    227. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002 Oct 15; 137(8):678-87. PMID: 12379069.
      Citations: 116     Fields:    Translation:Humans
    228. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002 Oct; 3 Suppl 2:S63-8. PMID: 12435294.
      Citations: 11     Fields:    Translation:Humans
    229. Buzdar AU. New generation aromatase inhibitors--from the advanced to the adjuvant setting. Breast Cancer Res Treat. 2002 Oct; 75 Suppl 1:S13-7; discussion S33-5. PMID: 12353818.
      Citations: 3     Fields:    Translation:Humans
    230. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95. PMID: 12177098.
      Citations: 134     Fields:    Translation:HumansCTClinical Trials
    231. Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, Buzdar AU, Buchholz TA. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33. PMID: 12128124.
      Citations: 12     Fields:    Translation:Humans
    232. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8. PMID: 12095553.
      Citations: 14     Fields:    Translation:Humans
    233. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22; 359(9324):2131-9. PMID: 12090977.
      Citations: 418     Fields:    Translation:HumansCTClinical Trials
    234. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002 Jun; 25(3):235-7. PMID: 12040279.
      Citations: 15     Fields:    Translation:Humans
    235. Assikis VJ, Buzdar A. Recent advances in aromatase inhibitor therapy for breast cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 11):120-8. PMID: 12138406.
      Citations:    Fields:    Translation:Humans
    236. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9. PMID: 12006521.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    237. Buzdar A, Hayes D, El-Khoudary A, Yan S, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P, Droloxifene 301 Study Group, L?nning P. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002 May; 73(2):161-75. PMID: 12088118.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    238. Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002 Apr; 9(3):228-34. PMID: 11923128.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    239. Buzdar AU. Superior efficacy of letrozole versus tamoxifen as first-line therapy. J Clin Oncol. 2002 Feb 01; 20(3):876-8. PMID: 11821477.
      Citations:    Fields:    Translation:Humans
    240. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002 Jan-Feb; 8(1):2-9. PMID: 11856154.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    241. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002 Jan 01; 20(1):17-23. PMID: 11773149.
      Citations: 32     Fields:    Translation:Humans
    242. Mackey JR, Joy AA. Letrozole in second-line therapy of advanced breast cancer: more questions than answers. J Clin Oncol. 2001 Dec 01; 19(23):4353-5. PMID: 11731524.
      Citations:    Fields:    Translation:Humans
    243. Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s. PMID: 11916221.
      Citations: 2     Fields:    Translation:Humans
    244. Johnson PE, Buzdar A. Are differences in the available aromatase inhibitors and inactivators significant? Clin Cancer Res. 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PMID: 11916226.
      Citations:    Fields:    Translation:Humans
    245. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8. PMID: 11839324.
      Citations: 18     Fields:    Translation:Humans
    246. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PMID: 11916233.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    247. Buzdar AU. A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001 Dec; 79(1-5):109-14. PMID: 11850214.
      Citations: 3     Fields:    Translation:Humans
    248. Johnston SR. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PMID: 11916228.
      Citations: 15     Fields:    Translation:Humans
    249. Goss PE. Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PMID: 11916231.
      Citations: 2     Fields:    Translation:Humans
    250. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001 Nov 15; 92(10):2523-8. PMID: 11745185.
      Citations: 56     Fields:    Translation:Humans
    251. Buzdar AU. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting? Br J Cancer. 2001 Nov; 85 Suppl 2:6-10. PMID: 11900212; PMCID: PMC2375168.
      Citations: 4     Fields:    Translation:Humans
    252. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee, Investigators Committee Members, Th?rlimann B. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001 Nov 01; 92(9):2247-58. PMID: 11745278.
      Citations: 99     Fields:    Translation:HumansCTClinical Trials
    253. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001 Oct 01; 92(7):1759-68. PMID: 11745247.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    254. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82. PMID: 11745249.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    255. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20. PMID: 11693900.
      Citations: 16     Fields:    Translation:Humans
    256. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001 Sep; 7(9):2620-35. PMID: 11555572.
      Citations: 23     Fields:    Translation:Humans
    257. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001 Jul 15; 19(14):3357-66. PMID: 11454883.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    258. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001 Jun; 28(3):291-304. PMID: 11402439.
      Citations: 23     Fields:    Translation:Humans
    259. Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, Buzdar AU, Singletary SE. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001 Jun; 8(5):425-31. PMID: 11407517.
      Citations: 32     Fields:    Translation:Humans
    260. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol. 2001 Jun; 77(2):139-47. PMID: 11398169.
      Citations: 3     Fields:    Translation:Humans
    261. Copur MS, Ledakis P, Bolton M, Norvell M, Muhvic J. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? J Clin Oncol. 2001 May 01; 19(9):2578; author reply 2580-2. PMID: 11331343.
      Citations: 1     Fields:    Translation:Humans
    262. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6. PMID: 11304777.
      Citations: 15     Fields:    Translation:Humans
    263. Newman LA, Kuerer HM, Fornage B, Mirza N, Hunt KK, Ross MI, Ames FC, Buzdar AU, Singletary SE. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg. 2001 Apr; 181(4):313-8. PMID: 11438265.
      Citations: 5     Fields:    Translation:Humans
    264. Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C, M?nster PN. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol. 2001 Apr 01; 19(7):2002-9. PMID: 11283133.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    265. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71. PMID: 11241232.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    266. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33. PMID: 11157012.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    267. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001; 6(2):133-46. PMID: 11306725.
      Citations: 31     Fields:    Translation:Humans
    268. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    269. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res. 2001; 7(3):171-7. PMID: 11692142.
      Citations: 18     Fields:    Translation:HumansCells
    270. Michaud LB, Jones KL, Buzdar AU. Combination endocrine therapy in the management of breast cancer. Oncologist. 2001; 6(6):538-46. PMID: 11743215.
      Citations: 6     Fields:    Translation:Humans
    271. Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol. 2000 Dec; 11(12):1597-601. PMID: 11205469.
      Citations: 7     Fields:    Translation:Humans
    272. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201. PMID: 11147589.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    273. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000 Nov 15; 18(22):3758-67. PMID: 11078488.
      Citations: 156     Fields:    Translation:HumansCTClinical Trials
    274. Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat. 2000 Nov; 64(2):157-63. PMID: 11194451.
      Citations: 18     Fields:    Translation:Humans
    275. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3480-6. PMID: 11032588.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    276. Buzdar AU. Tamoxifen's clinical applications: old and new. Arch Fam Med. 2000 Sep-Oct; 9(9):906-12. PMID: 11031399.
      Citations: 2     Fields:    Translation:Humans
    277. Buzdar A. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. Eur J Cancer. 2000 Sep; 36 Suppl 4:S82-4. PMID: 11056331.
      Citations:    Fields:    Translation:Humans
    278. Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, Buzdar AU, Singletary SE. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol. 2000 Sep; 7(8):581-7. PMID: 11005556.
      Citations: 18     Fields:    Translation:Humans
    279. Buzdar A. Exemestane in advanced breast cancer. Anticancer Drugs. 2000 Sep; 11(8):609-16. PMID: 11081451.
      Citations: 2     Fields:    Translation:Humans
    280. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, Hortobagyi G, Buzdar AU, Theriault R, Singletary SE, McNeese MD. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug; 18(15):2817-27. PMID: 10920129.
      Citations: 90     Fields:    Translation:Humans
    281. Liao Z, Strom EA, Buzdar AU, Singletary SE, Hunt K, Allen PK, McNeese MD. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000 Jul 15; 47(5):1191-200. PMID: 10889372.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    282. Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, Pollock RE, Newman LA, Feig BW, Strom EA, Buchholz TA, McNeese MD, Hortobagyi GN, Singletary SE. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40. PMID: 10894139.
      Citations: 5     Fields:    Translation:Humans
    283. Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Buzdar AU, Singletary SE. Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer. Breast J. 2000 Jul; 6(4):242-246. PMID: 11348372.
      Citations: 2     Fields:    
    284. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol. 2000 Jun; 23(3):319-21. PMID: 10857902.
      Citations: 11     Fields:    Translation:Humans
    285. Vlastos G, Fornage BD, Mirza NQ, Bedi D, Lenert JT, Winchester DJ, Tolley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Buzdar AU, Singletary SE. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg. 2000 Jun; 179(6):446-52. PMID: 11004328.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    286. Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser D, Asmar L, Frye D, McNeese MD, Hortobagyi GN. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 2000 May 01; 88(9):2054-60. PMID: 10813717.
      Citations: 5     Fields:    Translation:Humans
    287. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21. PMID: 10776969.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    288. Michaud LB, Buzdar AU. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging. 2000 Apr; 16(4):261-71. PMID: 10874521.
      Citations: 1     Fields:    Translation:Humans
    289. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology. 2000 Apr; 58(3):185-90. PMID: 10765118.
      Citations: 19     Fields:    Translation:Humans
    290. Buzdar AU, Chaudri HA, Trunet PF. Letrozole: which dose to be used? J Clin Oncol. 2000 Apr; 18(8):1802-3. PMID: 10764444.
      Citations:    Fields:    Translation:Humans
    291. Mavligit GM, Estrov Z. CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. Am J Clin Oncol. 2000 Apr; 23(2):213-5. PMID: 10776987.
      Citations: 3     Fields:    Translation:Humans
    292. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, Ross MI, Buzdar AU, Singletary SE. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer. 2000 Mar 15; 88(6):1417-24. PMID: 10717625.
      Citations: 12     Fields:    Translation:Humans
    293. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33. PMID: 10655439.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    294. Kushwaha AC, Whitman GJ, Stelling CB, Cristofanilli M, Buzdar AU. Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. AJR Am J Roentgenol. 2000 Feb; 174(2):535-8. PMID: 10658737.
      Citations: 5     Fields:    Translation:Humans
    295. Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G, Jones SE, Lazar GS, Spitzer G, Swain SM, Vaughn CB, Vogel CE, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant. 2000 Feb; 14(1):32-41. PMID: 10693633.
      Citations: 9     Fields:    Translation:Humans
    296. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000 Feb; 82(3):529-34. PMID: 10682660; PMCID: PMC2363337.
      Citations: 7     Fields:    Translation:Humans
    297. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3. PMID: 10675076.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    298. Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, Buzdar AU, Hortobagyi GN, Singletary SE. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol. 1999 Dec; 6(8):762-7. PMID: 10622504.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    299. Buzdar AU. Critique of survival update analysis from two phase III anastrozole clinical trials. Ann Surg Oncol. 1999 Dec; 6(8 Suppl):8S-11S. PMID: 10619453.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    300. Bland KI, Buzdar AU. Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer. Ann Surg Oncol. 1999 Dec; 6(8 Suppl):12S-13S. PMID: 10619454.
      Citations:    Fields:    Translation:Humans
    301. Robertson JF, Howell A, Buzdar A, von Euler M, Lee D. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat. 1999 Nov; 58(2):157-62. PMID: 10674881.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    302. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7. PMID: 10550135.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    303. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf. 1999 Oct; 21(4):297-309. PMID: 10514021.
      Citations: 6     Fields:    Translation:Humans
    304. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7. PMID: 10506711.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    305. Buzdar AU, Hortobagyi GN. Recent advances in adjuvant therapy of breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):21-7. PMID: 10482191.
      Citations: 1     Fields:    Translation:Humans
    306. Hortobagyi GN, Hung MC, Buzdar AU. Recent developments in breast cancer therapy. Semin Oncol. 1999 Aug; 26(4 Suppl 12):11-20. PMID: 10482190.
      Citations: 4     Fields:    Translation:Humans
    307. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230(1):72-8. PMID: 10400039; PMCID: PMC1420847.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    308. Buzdar AU. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):219-25. PMID: 10731112.
      Citations: 4     Fields:    Translation:Humans
    309. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34. PMID: 10334527.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    310. Buchholz TA, Hunt KK, Amosson CM, Tucker SL, Strom EA, McNeese MD, Buzdar AU, Singletary SE, Hortobagyi GN. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am. 1999 May-Jun; 5(3):159-64. PMID: 10367172.
      Citations: 5     Fields:    Translation:Humans
    311. Knoche AJ, Michaud LB, Buzdar AU. Efficacy of Anastrozole in a Consecutive Series of Advanced Breast Cancer Patients Treated with Multiple Prior Chemotherapies and Endocrine Agents: M. D. Anderson Cancer Center Experience. Breast J. 1999 May; 5(3):176-181. PMID: 11348281.
      Citations: 1     Fields:    
    312. Cristofanilli M, Holmes FA, Esparza L, Valero V, Buzdar AU, Neidhart JA, Hortobagyi GN. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat. 1999 Apr; 54(3):225-33. PMID: 10445421.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    313. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11. PMID: 10370782.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    314. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999 Mar; 17(3):855-61. PMID: 10071276.
      Citations: 45     Fields:    Translation:Humans
    315. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17(2):460-9. PMID: 10080586.
      Citations: 351     Fields:    Translation:HumansCTClinical Trials
    316. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999 Feb; 17(2):485-93. PMID: 10080589.
      Citations: 143     Fields:    Translation:HumansCTClinical Trials
    317. Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1999; 43(6):471-8. PMID: 10321507.
      Citations: 8     Fields:    Translation:Humans
    318. Buzdar AU, Hortobagyi GN. Breast cancer. Cancer Chemother Biol Response Modif. 1999; 18:435-69. PMID: 10800497.
      Citations:    Fields:    Translation:Humans
    319. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999 Jan 01; 85(1):104-11. PMID: 9921981.
      Citations: 25     Fields:    Translation:Humans
    320. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9. PMID: 9926779.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    321. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol. 1998 Dec; 16(12):3731-5. PMID: 9850015.
      Citations: 37     Fields:    Translation:Humans
    322. Kuerer HM, Newman LA, Fornage BD, Dhingra K, Hunt KK, Buzdar AU, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 1998 Dec; 5(8):673-80. PMID: 9869512.
      Citations: 11     Fields:    Translation:Humans
    323. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998 Sep 15; 83(6):1142-52. PMID: 9740079.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    324. Buzdar A. The place of chemotherapy in the treatment of early breast cancer. Br J Cancer. 1998 Sep; 78 Suppl 4:16-20. PMID: 9741784; PMCID: PMC2062752.
      Citations: 5     Fields:    Translation:Humans
    325. Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev. 1998 Aug; 24(4):249-63. PMID: 9805506.
      Citations:    Fields:    Translation:Humans
    326. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998 Jul-Aug; 4(4):230-6. PMID: 9689981.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    327. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998 Jun 15; 82(12):2366-72. PMID: 9635529.
      Citations: 69     Fields:    Translation:Humans
    328. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 May 16; 351(9114):1451-67. PMID: 9605801.
      Citations: 778     Fields:    Translation:Humans
    329. Williams GM. Differences in toxicity findings for antiestrogens. J Clin Oncol. 1998 May; 16(5):1999-2000. PMID: 9586922.
      Citations:    Fields:    Translation:Humans
    330. Diaz-Canton EA, Valero V, Rahman Z, Rodriguez-Monge E, Frye D, Smith T, Buzdar AU, Hortobagyi GN. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol. 1998 Apr; 9(4):413-8. PMID: 9636832.
      Citations: 10     Fields:    Translation:Humans
    331. Buzdar AU. Anastrozole: a new addition to the armamentarium against advanced breast cancer. Am J Clin Oncol. 1998 Apr; 21(2):161-6. PMID: 9537204.
      Citations: 1     Fields:    Translation:Humans
    332. Adkins DR, Brown RA, DiPersio JF. Patient selection in high-dose trials of breast cancer. J Clin Oncol. 1998 Mar; 16(3):1238-9. PMID: 9508217.
      Citations:    Fields:    Translation:Humans
    333. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res. 1998 Mar; 4(3):527-34. PMID: 9533518.
      Citations: 15     Fields:    Translation:Humans
    334. Hortobagyi GN, Buzdar AU. Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. Cancer Invest. 1998; 16(6):385-90. PMID: 9679529.
      Citations: 2     Fields:    Translation:Humans
    335. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol. 1998 Jan; 16(1):348-53. PMID: 9440763.
      Citations: 15     Fields:    Translation:HumansAnimals
    336. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 1997 Dec 15; 80(12):2240-9. PMID: 9404700.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    337. Roseman BJ, Buzdar AU, Singletary SE. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol. 1997 Nov; 66(3):215-20. PMID: 9369969.
      Citations: 2     Fields:    Translation:Humans
    338. Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-65-S17-68. PMID: 9374097.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    339. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997 Oct; 15(10):3171-7. PMID: 9336352.
      Citations: 8     Fields:    Translation:Humans
    340. Buzdar AU, Hortobagyi GN, Asmar L, Theriault RL, Rahman Z, McNeese M, Singletary S, Ames F. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-31-S17-34. PMID: 9374089.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    341. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Buzdar AU, Podoloff DA. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging. 1997 Sep-Oct; 21(5):332-6. PMID: 9316752.
      Citations: 2     Fields:    Translation:Humans
    342. Fleming RY, Asmar L, Buzdar AU, McNeese MD, Ames FC, Ross MI, Singletary SE. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997 Sep; 4(6):452-61. PMID: 9309333.
      Citations: 20     Fields:    Translation:Humans
    343. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1997 Sep; 3(9):1565-9. PMID: 9815844.
      Citations: 35     Fields:    Translation:Humans
    344. Buzdar AU, Asmar L, Hortobagyi GN. Impact of patient characteristics on treatment outcome: anthracycline resistance. Eur J Cancer. 1997 Aug; 33 Suppl 7:S3-6. PMID: 9486095.
      Citations:    Fields:    Translation:Humans
    345. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, Buzdar AU. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 11):S11-13-S11-19. PMID: 9314293.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    346. Buzdar AU, Jonat W, Howell A, Plourde PV. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. J Steroid Biochem Mol Biol. 1997 Apr; 61(3-6):145-9. PMID: 9365184.
      Citations: 6     Fields:    Translation:Humans
    347. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer. 1997 Feb 15; 79(4):730-9. PMID: 9024711.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    348. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 3):S30-3. PMID: 9071338.
      Citations:    Fields:    Translation:Humans
    349. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40(4):321-9. PMID: 9225950.
      Citations: 66     Fields:    Translation:Humans
    350. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21. PMID: 8874332.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    351. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996 Oct; 14(10):2722-30. PMID: 8874333.
      Citations: 19     Fields:    Translation:Humans
    352. Buzdar AU, Plourde PV, Hortobagyi GN. Aromatase inhibitors in metastatic breast cancer. Semin Oncol. 1996 Aug; 23(4 Suppl 9):28-32. PMID: 8824462.
      Citations: 1     Fields:    Translation:Humans
    353. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996 Aug; 14(8):2197-205. PMID: 8708708.
      Citations: 160     Fields:    Translation:Humans
    354. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Cherif A, Delpassand E, Buzdar A, Podoloff DA. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm. 1996 Aug; 11(4):235-45. PMID: 10851543.
      Citations: 12     Fields:    Translation:Humans
    355. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996 Jul; 14(7):2000-11. PMID: 8683230.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    356. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13. PMID: 8640699.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    357. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buzdar AU, Podoloff DA. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med. 1996 Jun; 37(6):931-8. PMID: 8683314.
      Citations: 25     Fields:    Translation:Humans
    358. Payne JY, Holmes F, Cohen PR, Gagel R, Buzdar A, Dhingra K. Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. South Med J. 1996 May; 89(5):542-5. PMID: 8638189.
      Citations: 7     Fields:    Translation:Humans
    359. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8. PMID: 8774207.
      Citations: 9     Fields:    Translation:Humans
    360. Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. Surg Clin North Am. 1996 Apr; 76(2):393-410. PMID: 8610271.
      Citations: 6     Fields:    Translation:Humans
    361. Mora EM, Singletary SE, Buzdar AU, Johnston DA. Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients. Ann Surg Oncol. 1996 Mar; 3(2):162-8. PMID: 8646517.
      Citations: 3     Fields:    Translation:Humans
    362. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94. PMID: 8523051.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    363. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995 Oct; 4(4):715-34. PMID: 8535907.
      Citations: 20     Fields:    Translation:Humans
    364. Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. Am J Clin Oncol. 1995 Oct; 18(5):407-17. PMID: 7572758.
      Citations: 1     Fields:    Translation:HumansAnimals
    365. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res. 1995 Jul 15; 55(14):3060-7. PMID: 7606728.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    366. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995 Jul; 1(7):691-7. PMID: 9816034.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    367. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin. 1995 Jul-Aug; 45(4):199-226. PMID: 7600278.
      Citations: 11     Fields:    Translation:Humans
    368. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol. 1995 Jun; 22(3 Suppl 6):101-4. PMID: 7541151.
      Citations: 3     Fields:    Translation:Humans
    369. Hortobagyi GN, Buzdar AU, Strom EA, Ames FC, Singletary SE. Primary chemotherapy for early and advanced breast cancer. Cancer Lett. 1995 Mar 23; 90(1):103-9. PMID: 7720036.
      Citations: 5     Fields:    Translation:Humans
    370. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995 Feb; 13(2):513-29. PMID: 7844613.
      Citations: 86     Fields:    Translation:Humans
    371. Buzdar AU, Esparza L, Natale R, Cody R, Calzone K, Benson AB, Sheehan T, Berry W. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. Am J Clin Oncol. 1994 Oct; 17(5):417-21. PMID: 8092114.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    372. Hortobagyi GN, Holmes FA, Theriault RL, Buzdar AU. Use of Taxol (paclitaxel) in breast cancer. Oncology. 1994 Oct; 51 Suppl 1:29-32. PMID: 7970507.
      Citations: 6     Fields:    Translation:Humans
    373. Mondzac AM. Tamoxifen dosage and bioequivalence: a correction. J Clin Oncol. 1994 Sep; 12(9):1993-4. PMID: 8083720.
      Citations:    Fields:    Translation:Humans
    374. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994 Apr 15; 73(8):2157-67. PMID: 8156520.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    375. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6. PMID: 8281625.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    376. Dhingra K, Valero V, Gutierrez L, Theriault R, Booser D, Holmes F, Buzdar A, Fraschini G, Hortobagyi G. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs. 1994; 12(3):235-41. PMID: 7896543.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    377. Yang DJ, Li C, Kuang LR, Price JE, Buzdar AU, Tansey W, Cherif A, Gretzer M, Kim EE, Wallace S. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci. 1994; 55(1):53-67. PMID: 8015349.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    378. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg. 1994 Jan-Feb; 18(1):87-92. PMID: 8197782.
      Citations: 3     Fields:    Translation:Humans
    379. Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol. 1994 Jan; 12(1):50-4. PMID: 8270984.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    380. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med. 1994 Jan 01; 120(1):18-25. PMID: 8250452.
      Citations: 37     Fields:    Translation:Humans
    381. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, Buzdar A, et al. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Adv Exp Med Biol. 1994; 353:193-202. PMID: 7985538.
      Citations: 1     Fields:    Translation:HumansAnimalsCTClinical Trials
    382. Buzdar AU, Kau SW, Smith TL, Ames F, Singletary E, Strom E, McNeese M, Hortobagyi GN. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer. 1993 Jun 01; 71(11):3680-4. PMID: 8490917.
      Citations: 5     Fields:    Translation:Humans
    383. LeBlond RF. Carcinoma of the male breast. Ann Intern Med. 1993 May 01; 118(9):749. PMID: 8460868.
      Citations:    Fields:    Translation:Humans
    384. Cohen PR, Buzdar AU. Metastatic breast carcinoma mimicking an acute paronychia of the great toe: case report and review of subungual metastases. Am J Clin Oncol. 1993 Feb; 16(1):86-91. PMID: 8424412.
      Citations: 3     Fields:    Translation:Humans
    385. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9. PMID: 7912522.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    386. Buzdar AU, Hortob?gyi GN. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs. 1993; 45 Suppl 2:10-9; discussion 18-9. PMID: 7693417.
      Citations: 9     Fields:    Translation:Humans
    387. Theriault RL, Stallings CB, Buzdar AU. Pregnancy and breast cancer: clinical and legal issues. Am J Clin Oncol. 1992 Dec; 15(6):535-9. PMID: 1333169.
      Citations: 1     Fields:    Translation:Humans
    388. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med. 1992 Nov 01; 117(9):771-7. PMID: 1416579.
      Citations: 13     Fields:    Translation:Humans
    389. Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol. 1992 Oct; 10(10):1540-6. PMID: 1403033.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    390. Voravud N, el-Naggar AK, Balch CM, Theriault RL. Metastatic lobular breast carcinoma simulating primary colon cancer. Am J Clin Oncol. 1992 Aug; 15(4):365-9. PMID: 1514536.
      Citations: 5     Fields:    Translation:Humans
    391. Vassilopoulou-Sellin R, Cangir A, Samaan NA. Acanthosis nigricans and severe insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy. Am J Clin Oncol. 1992 Jun; 15(3):273-6. PMID: 1590285.
      Citations: 1     Fields:    Translation:Humans
    392. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992 Jun; 10(6):1014-24. PMID: 1588366.
      Citations: 79     Fields:    Translation:Humans
    393. Jaiyesimi IA, Buzdar AU. Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes. Am J Clin Oncol. 1992 Apr; 15(2):180-3. PMID: 1313203.
      Citations:    Fields:    Translation:Humans
    394. Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992 Jan 15; 69(2):448-52. PMID: 1728373.
      Citations: 11     Fields:    Translation:Humans
    395. Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15; 69(2):476-81. PMID: 1728377.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    396. Simmons JR, Buzdar AU, Ota DM, Marts K, Hortobagyi GN. Complications associated with indwelling catheters. Med Pediatr Oncol. 1992; 20(1):22-5. PMID: 1727207.
      Citations: 1     Fields:    Translation:Humans
    397. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18; 83(24):1797-805. PMID: 1683908.
      Citations: 141     Fields:    Translation:HumansCTClinical Trials
    398. Fraschini G, Holmes FA, Esparza L, Theriault RL, Buzdar AU, Hortobagyi GN. Phase I-II study of high-dose etoposide in patients with refractory breast cancer. Invest New Drugs. 1991 Nov; 9(4):365-7. PMID: 1804815.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    399. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1991 Aug; 18(3):165-70. PMID: 1756259.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    400. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med. 1991 Jul; 32(7):1326-32. PMID: 2066785.
      Citations: 12     Fields:    Translation:Humans
    401. Ziegler LD, Buzdar AU. Recent advances in the treatment of breast cancer. Am J Med Sci. 1991 May; 301(5):337-52. PMID: 2021157.
      Citations:    Fields:    Translation:Humans
    402. Ziegler LD, Buzdar AU. Current status of adjuvant therapy of early breast cancer. Am J Clin Oncol. 1991 Apr; 14(2):101-10. PMID: 2028918.
      Citations: 3     Fields:    Translation:Humans
    403. Wallerstein R, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol. 1990 Nov; 8(11):1782-8. PMID: 2121909.
      Citations: 5     Fields:    Translation:Humans
    404. Buzdar AU, Hortobagyi GN. Sixteen-week, dose-intense chemotherapy in adjuvant treatment of breast cancer. J Natl Cancer Inst. 1990 Jul 18; 82(14):1220-1. PMID: 2362293.
      Citations:    Fields:    Translation:Humans
    405. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol. 1990 Jul; 8(7):1207-16. PMID: 2358837.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    406. Holmes FA, Fritsche HA, Loewy JW, Geitner AM, Sutton RC, Buzdar AU, Hortobagyi GN. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol. 1990 Jun; 8(6):1025-35. PMID: 2189952.
      Citations: 5     Fields:    Translation:Humans
    407. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990 Feb 15; 65(4):847-50. PMID: 2297653.
      Citations: 19     Fields:    Translation:Humans
    408. Buzdar AU, McNeese MD, Hortobagyi GN, Smith TL, Kau S, Fraschini G, Hug V, Ellerbroek N, Holmes FA, Ames F, et al. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer. 1990 Feb 01; 65(3):394-9. PMID: 2297630.
      Citations: 9     Fields:    Translation:Humans
    409. Theriault RL, Buzdar AU. Acute superior vena caval thrombosis after central venous catheter removal: successful treatment with thrombolytic therapy. Med Pediatr Oncol. 1990; 18(1):77-80. PMID: 2152960.
      Citations: 2     Fields:    Translation:Humans
    410. Hortobagyi GN, Dunphy F, Buzdar AU, Spitzer G. Dose intensity studies in breast cancer--autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 354B:195-209. PMID: 2236166.
      Citations:    Fields:    Translation:Humans
    411. Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol. 1990; 27(2):94-100. PMID: 2249339.
      Citations: 4     Fields:    Translation:Humans
    412. Buzdar AU, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G, Lichtiger B. Elliptinium acetate in metastatic breast cancer--a phase II study. Oncology. 1990; 47(2):101-4. PMID: 2314820.
      Citations: 3     Fields:    Translation:Humans
    413. Vanek N, Hortobagyi GN, Buzdar AU. Radiotherapy enhances the toxicity of aminoglutethimide. Med Pediatr Oncol. 1990; 18(2):162-4. PMID: 2154663.
      Citations:    Fields:    Translation:Humans
    414. Buzdar AU. Current status of endocrine treatment of carcinoma of the breast. Semin Surg Oncol. 1990; 6(2):77-82. PMID: 2180045.
      Citations:    Fields:    Translation:Humans
    415. Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol. 1990; 13 Suppl 1:S54-6. PMID: 2291460.
      Citations: 2     Fields:    Translation:Humans
    416. Ang PT, Buzdar AU, Smith TL, Kau S, Hortobagyi GN. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol. 1989 Nov; 7(11):1677-84. PMID: 2809682.
      Citations: 8     Fields:    Translation:Humans
    417. Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989 Oct 15; 64(8):1583-5. PMID: 2676137.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    418. Thoms WW, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):739-45. PMID: 2487034.
      Citations: 13     Fields:    Translation:Humans
    419. Hortobagyi GN, Hug V, Buzdar AU, Kau SW, Holmes FA, Fritsche HA. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer. 1989 Sep 01; 64(5):1002-6. PMID: 2527085.
      Citations: 1     Fields:    Translation:Humans
    420. Merkel DE, Fuqua SA, Tandon AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol. 1989 Aug; 7(8):1129-36. PMID: 2569033.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    421. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989 Apr; 12(2):123-8. PMID: 2705401.
      Citations: 9     Fields:    Translation:Humans
    422. Theriault RL, Hortobagyi GN, Fritsche HA, Frye D, Martinez R, Buzdar AU. The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer. 1989 Mar 01; 63(5):828-35. PMID: 2914290.
      Citations: 3     Fields:    Translation:Humans
    423. Chu PS, Buzdar AU, Hortobagyi GN. Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res Treat. 1989 Mar; 13(2):117-21. PMID: 2659103.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    424. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989 Jan 01; 63(1):37-45. PMID: 2910423.
      Citations: 35     Fields:    Translation:Humans
    425. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989 Jan; 124(1):21-5. PMID: 2910244.
      Citations: 27     Fields:    Translation:Humans
    426. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988 12 29; 319(26):1681-92. PMID: 3205265.
      Citations: 143     Fields:    Translation:Humans
    427. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988 Dec 15; 62(12):2507-16. PMID: 3056604.
      Citations: 74     Fields:    Translation:Humans
    428. Buzdar AU, Hortobagyi GN, Smith TL, Kau S, Marcus C, Holmes FA, Hug V, Fraschini G, Ames FC, Martin RG. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988 Nov 15; 62(10):2098-104. PMID: 3179922.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    429. Theriault RL, Hortobagyi GN, Kau SW, Holmes FA, Hug V, Fraschini G, Jabboury K, Buzdar AU. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer. 1988 Nov 15; 62(10):2105-10. PMID: 3179923.
      Citations: 1     Fields:    Translation:Humans
    430. Hortobagyi GN, Buzdar AU. Management of locally advanced breast cancer. Am J Clin Oncol. 1988 Oct; 11(5):597-601. PMID: 2845771.
      Citations: 3     Fields:    Translation:Humans
    431. Fraschini G, Holmes FA, Buzdar AU, Hug V, Hortobagyi GN. Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer. Am J Clin Oncol. 1988 Aug; 11(4):448-50. PMID: 3407623.
      Citations:    Fields:    Translation:Humans
    432. Skinner WL, Buzdar AU, Libshitz HI. Massive osteolysis of the right clavicle developing after radiation therapy. JAMA. 1988 Jul 15; 260(3):375-6. PMID: 3379746.
      Citations:    Fields:    Translation:HumansPHPublic Health
    433. Buzdar AU. Chemotherapeutic approaches to advanced breast cancer. Semin Oncol. 1988 Jun; 15(3 Suppl 4):65-70. PMID: 3293220.
      Citations: 1     Fields:    Translation:Humans
    434. Buzdar AU, Smith TL, Hortobagyi GN, Bert? E. Bilateral primary breast cancer in patients treated with adjuvant therapy. Am J Clin Oncol. 1988 Apr; 11(2):114-8. PMID: 3128945.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    435. Fraschini G, Charnsangavej C, Carrasco CH, Buzdar AU, Jabboury KW, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol. 1988 Feb; 11(1):34-8. PMID: 3277374.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    436. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology. 1988; 45(5):344-5. PMID: 3412740.
      Citations: 29     Fields:    Translation:Humans
    437. Hortobagyi GN, Buzdar AU, Frye D, Hug V, Fraschini G, Ames FC, Montague E, Gutterman JU, Martin RG. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. Cancer. 1987 Dec 01; 60(11):2596-604. PMID: 3315173.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    438. Hortobagyi GN, Frye D, Holmes FA, Hug V, Fraschini G, Buzdar AU. Phase II study of iproplatin in metastatic breast carcinoma. Cancer Treat Rep. 1987 Dec; 71(12):1193-6. PMID: 3690529.
      Citations: 1     Fields:    Translation:Humans
    439. Fraschini G, Yap HY, Mann G, Buzdar AU, Blumenschein GR, Hortobagyi GN. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer. 1987 Oct 15; 60(8):1724-8. PMID: 3652000.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    440. Moon TE, Jones SE, Bonadonna G, Valagussa P, Powles T, Buzdar A, Montague E. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol. 1987 Oct; 10(5):396-403. PMID: 3310604.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    441. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol. 1987 Oct; 10(5):387-95. PMID: 3310603.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    442. Ro J, Buzdar AU, Esparza L, Hortobagyi GN. Phase II study of peplomycin in advanced breast carcinoma. Cancer Treat Rep. 1987 Jul-Aug; 71(7-8):777-8. PMID: 2440571.
      Citations:    Fields:    Translation:Humans
    443. Holmes FA, Yap HY, Esparza L, Buzdar AU, Blumenschein GR, Hug V, Hortobagyi GN. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer. 1987 Jun 15; 59(12):1992-9. PMID: 3567861.
      Citations: 3     Fields:    Translation:HumansCells
    444. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987 May; 5(5):773-82. PMID: 3106583.
      Citations: 36     Fields:    Translation:Humans
    445. Ventura GJ, Buzdar AU, Kau S, Lichtiger B, Hortobagyi GN. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer. Cancer Treat Rep. 1987 Apr; 71(4):411-3. PMID: 3548958.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    446. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar; 5(3):354-64. PMID: 3819804.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    447. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol. 1987 Feb; 5(2):178-84. PMID: 3543241.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    448. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986 Dec 15; 58(12):2589-93. PMID: 3779609.
      Citations: 28     Fields:    Translation:Humans
    449. Larroquette CA, Hortobagyi GN, Buzdar AU, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. JAMA. 1986 Dec 05; 256(21):2988-90. PMID: 3773217.
      Citations: 5     Fields:    Translation:Humans
    450. Kramer A, Buzdar AU. Inflammatory breast carcinoma. Am J Clin Oncol. 1986 Dec; 9(6):541-3. PMID: 3024479.
      Citations:    Fields:    Translation:Humans
    451. Hortobagyi GN, Buzdar AU. Progress in inflammatory breast cancer: cause for cautious optimism. J Clin Oncol. 1986 Dec; 4(12):1727-9. PMID: 3783199.
      Citations: 1     Fields:    Translation:Humans
    452. Theriault RL, Hortobagyi GN, Buzdar AU, Levy HB, Hersh EM. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. Cancer Treat Rep. 1986 Nov; 70(11):1341-2. PMID: 3768878.
      Citations: 2     Fields:    Translation:Humans
    453. Janjan NA, McNeese MD, Buzdar AU, Montague ED, Oswald MJ. Management of locoregional recurrent breast cancer. Cancer. 1986 Oct 01; 58(7):1552-6. PMID: 3755648.
      Citations: 7     Fields:    Translation:Humans
    454. Polyzos A, Buzdar AU. Complete remission with combination chemotherapy in metastatic breast carcinoma. Am J Clin Oncol. 1986 Aug; 9(4):361-3. PMID: 3751975.
      Citations:    Fields:    Translation:Humans
    455. Herring MK, Buzdar AU, Smith TL, Hortobagyi GN, Blumenschein GR. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol. 1986 Jun; 9(3):269-75. PMID: 3755282.
      Citations: 6     Fields:    Translation:Humans
    456. Buzdar AU, Hortobagyi GN. Adjuvant chemotherapy for breast cancer. JAMA. 1986 May 02; 255(17):2296. PMID: 3959318.
      Citations:    Fields:    Translation:Humans
    457. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May; 46(5):2578-81. PMID: 3697997.
      Citations: 65     Fields:    Translation:Humans
    458. Casimir MT, Buzdar AU, Blumenschein GR, Hortobagyi GN, Bodey GP. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology. 1986; 43(4):205-7. PMID: 3755230.
      Citations:    Fields:    Translation:Humans
    459. Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986; 18(2):157-61. PMID: 3791560.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    460. Buzdar AU, Hortobagyi GN, Marcus CE, Smith TL, Martin R, Gehan EA. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; (1):81-5. PMID: 3534594.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    461. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; (1):105-9. PMID: 3534581.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    462. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3. PMID: 3940620.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    463. Hortobagyi GN, Buzdar AU, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63. PMID: 3596041.
      Citations:    Fields:    Translation:Humans
    464. Pasterz RB, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1985 Nov 15; 56(10):2381-4. PMID: 4042070.
      Citations: 3     Fields:    Translation:Humans
    465. Mann GB, Hortobagyi GN, Buzdar AU, Yap HY, Valdivieso M. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. Cancer. 1985 Sep 15; 56(6):1320-4. PMID: 4027872.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    466. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC. Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep. 1985 Sep; 69(9):1003-4. PMID: 4028032.
      Citations: 4     Fields:    Translation:Humans
    467. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer. 1985 Jul 15; 56(2):225-9. PMID: 4005794.
      Citations: 7     Fields:    Translation:Humans
    468. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985 Jun 15; 55(12):2761-5. PMID: 3922612.
      Citations: 80     Fields:    Translation:Humans
    469. Fastenberg NA, Martin RG, Buzdar AU, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41. PMID: 3841746.
      Citations: 3     Fields:    Translation:Humans
    470. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer. 1985 Jan 15; 55(2):341-6. PMID: 3965092.
      Citations: 17     Fields:    Translation:Humans
    471. Yau JC, Yap YY, Buzdar AU, Hortobagyi GN, Bodey GP, Blumenschein GR. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer. 1985 Jan 15; 55(2):337-40. PMID: 3880657.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    472. Buzdar AU, Hortobagyi GN. Comment on 'Long-term tamoxifen adjuvant therapy in node positive breast cancer'. Breast Cancer Res Treat. 1985; 6(2):149-50. PMID: 4052642.
      Citations:    Fields:    Translation:Humans
    473. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6. PMID: 3161565.
      Citations: 11     Fields:    Translation:Humans
    474. Feldman LD, Buzdar AU, Blumenschein GR. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology. 1985; 42(5):273-4. PMID: 4034143.
      Citations:    Fields:    Translation:Humans
    475. Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR, Montague ED. Induction chemotherapy of breast cancer. Prog Clin Biol Res. 1985; 201:105-16. PMID: 4095105.
      Citations:    Fields:    Translation:Humans
    476. Buzdar AU, Blumenschein GR. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9. PMID: 6534512.
      Citations:    Fields:    Translation:Humans
    477. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61. PMID: 6548710.
      Citations: 3     Fields:    Translation:Humans
    478. Moon TE, Jones SE, Bonadonna G, Powles TJ, Rivkin S, Buzdar A, Montague E. Using a database of protocol studies to evaluate therapy: a breast cancer example. Stat Med. 1984 Oct-Dec; 3(4):333-9. PMID: 6528133.
      Citations:    Fields:    Translation:Humans
    479. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31. PMID: 6385262.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    480. Buzdar AU. Adjuvant therapy of breast cancer. Tex Med. 1984 Sep; 80(9):37-8. PMID: 6484865.
      Citations:    Fields:    Translation:Humans
    481. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep. 1984 Jul-Aug; 68(7-8):1039-41. PMID: 6547638.
      Citations: 2     Fields:    Translation:Humans
    482. Aboud A, Buzdar AU, Yap HY, Hortobagyi GN, Blumenschein GR. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. J Surg Oncol. 1984 Jul; 26(3):205-7. PMID: 6610802.
      Citations:    Fields:    Translation:Humans
    483. Smith L, Buzdar AU, Rusch V, Blocker SH, McKenna RJ. Post-mastectomy angiosarcoma: case report and review of the literature. Tex Med. 1984 Jul; 80(7):43-4. PMID: 6379971.
      Citations:    Fields:    Translation:Humans
    484. Finnerty NA, Buzdar AU, Blumenschein GR. Radiation-induced breast cancer. Arch Intern Med. 1984 Jun; 144(6):1217-9. PMID: 6732380.
      Citations: 1     Fields:    Translation:Humans
    485. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40. PMID: 6231092.
      Citations: 1     Fields:    Translation:Humans
    486. Pinnamaneni K, Yap HY, Buzdar AU, Distefano A, Blumenschein GR. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer. 1984 May 01; 53(9):1841-4. PMID: 6546706.
      Citations: 1     Fields:    Translation:Humans
    487. Chawla SP, Buzdar AU, Hortobagyi GN, Blumenschein GR. Tumor-associated fever in breast cancer. Cancer. 1984 Apr 01; 53(7):1596-9. PMID: 6697296.
      Citations: 2     Fields:    Translation:Humans
    488. Buzdar AU, Blumenschein GR, Montague ED, Hortobagyi GN, Yap HY, Pinnamaneni K, Marcus CE, Smith TL. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984 Feb; 7(1):45-50. PMID: 6364779.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    489. Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Ames FC, Martin RG, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984 Feb 01; 53(3):384-9. PMID: 6362814.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    490. Buzdar AU, Fraschini G, Blumenschein GR. Hematologic adverse effects of aminoglutethimide. Ann Intern Med. 1984 Jan; 100(1):159. PMID: 6691645.
      Citations: 3     Fields:    Translation:Humans
    491. Combined endocrine and chemotherapy--any true benefits? Breast Cancer Res Treat. 1984; 4(4):251-9. PMID: 6518291.
      Citations:    Fields:    Translation:Humans
    492. Blumenschein GR, Buzdar AU, Hortobagyi GN. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. Recent Results Cancer Res. 1984; 96:129-32. PMID: 6528087.
      Citations:    Fields:    Translation:Humans
    493. Buzdar AU, Smith TL, Marcus CE, Hortobagyi GN, Blumenschein GR. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results Cancer Res. 1984; 96:141-7. PMID: 6396767.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    494. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU, Blumenschein GR. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec; 1(12):776-86. PMID: 6668494.
      Citations: 33     Fields:    Translation:Humans
    495. Harkins LA, Yap HY, Buzdar AU, Blumenschein GR. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients. Cancer. 1983 Oct 01; 52(7):1308-11. PMID: 6883292.
      Citations: 1     Fields:    Translation:Humans
    496. Ali MK, Buzdar AU, Ewer MS, Cheng RS, Haynie TP. Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer. J Surg Oncol. 1983 Jul; 23(3):212-6. PMID: 6865442.
      Citations: 2     Fields:    Translation:Humans
    497. Hall SM, Buzdar AU, Blumenschein GR. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer. 1983 Jul 01; 52(1):180-4. PMID: 6850542.
      Citations: 7     Fields:    Translation:Humans
    498. DeMartini AL, Buzdar AU, Blumenschein GR. Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. J Surg Oncol. 1983 May; 23(1):32-4. PMID: 6687746.
      Citations: 3     Fields:    Translation:Humans
    499. Hortobagyi GN, Spanos W, Montague ED, Buzdar AU, Yap HY, Blumenschein GR. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys. 1983 May; 9(5):643-50. PMID: 6343312.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    500. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6. PMID: 6834584.
      Citations: 10     Fields:    Translation:Humans
    501. Hortobagyi GN, Yap HY, Blumenschein GR, Buzdar AU, Barnes BC, Legha SS, Wiseman CL. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72. PMID: 6600415.
      Citations: 2     Fields:    Translation:Humans
    502. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8. PMID: 6687377.
      Citations: 32     Fields:    Translation:Humans
    503. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40. PMID: 6824391.
      Citations: 12     Fields:    Translation:Humans
    504. Buzdar AU, Powell KC, Legha SS, Blumenschein GR. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer. 1982 Nov 01; 50(9):1708-12. PMID: 6180820.
      Citations: 4     Fields:    Translation:Humans
    505. Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU, Schell FC, Bodey GP. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol. 1982 Oct; 5(5):511-4. PMID: 7180829.
      Citations: 1     Fields:    Translation:Humans
    506. Buzdar AU, Legha SS, Hortobagyi GN, Powell KC, Blumenschein GR, Bodey GP. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol. 1982 Aug; 5(4):383-7. PMID: 6896794.
      Citations:    Fields:    Translation:Humans
    507. Buzdar AU, Powell KC, Blumenschein GR. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res. 1982 Aug; 42(8 Suppl):3448s-3450s. PMID: 7083209.
      Citations: 4     Fields:    Translation:Humans
    508. Buzdar AU, Legha SS, Blumenschein GR, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Fraschini G, Bodey GP. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer. 1982 May 01; 49(9):1767-70. PMID: 7042074.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    509. Ross MB, Buzdar AU, Blumenschein GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7. PMID: 6174195.
      Citations: 5     Fields:    Translation:Humans
    510. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982; 2(2):163-9. PMID: 6897369.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    511. Ross MB, Buzdar AU, Hortobagyi GN, Lukeman JM. Spontaneous regression of breast carcinoma: follow-up report and literature review. J Surg Oncol. 1982 Jan; 19(1):22-4. PMID: 7057640.
      Citations: 4     Fields:    Translation:Humans
    512. Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med. 1981 Dec; 95(6):694-7. PMID: 7305147.
      Citations: 29     Fields:    Translation:Humans
    513. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9. PMID: 7273012.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    514. Rodriguez-Kraul R, Hortobagyi GN, Buzdar AU, Blumenschein GR. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer. 1981 Jul 15; 48(2):227-32. PMID: 7237395.
      Citations: 4     Fields:    Translation:Humans
    515. Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 1981 Jun 15; 47(12):2798-802. PMID: 7260870.
      Citations: 12     Fields:    Translation:Humans
    516. Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981 Jun 15; 47(12):2803-6. PMID: 7260871.
      Citations: 10     Fields:    Translation:Humans
    517. Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer. 1981 Jun 01; 47(11):2537-42. PMID: 6790155.
      Citations: 5     Fields:    Translation:Humans
    518. Hortobagyi GN, Smith TL, Swenerton KD, Legha SS, Buzdar AU, Blumenschein GR, Gutterman JU, Hersh EM. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer. 1981 Mar 15; 47(6):1369-76. PMID: 7226061.
      Citations: 2     Fields:    Translation:Humans
    519. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981 Feb 01; 47(3):554-60. PMID: 7226005.
      Citations: 52     Fields:    Translation:Humans
    520. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY, Schell FC, Barnes BC, Burgess MA. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981; 18(2):163-72. PMID: 7300363.
      Citations: 1     Fields:    Translation:Humans
    521. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep; 93(3):399-406. PMID: 6159812.
      Citations: 91     Fields:    Translation:HumansCells
    522. Legha SS, Buzdar AU, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer. 1980 Aug 01; 46(3):438-45. PMID: 7397619.
      Citations: 2     Fields:    Translation:Humans
    523. Hagemeister FB, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 01; 46(1):162-7. PMID: 7388758.
      Citations: 38     Fields:    Translation:Humans
    524. Hug V, Hortobagyi GN, Buzdar AU, Blumenschein GR, Grose W, Burgess MA, Bodey GP. A phase II study of peptichemio in advanced breast cancer. Cancer. 1980 May 15; 45(10):2524-8. PMID: 7378988.
      Citations: 5     Fields:    Translation:Humans
    525. Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Hersh EM. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer. 1980 Feb 15; 45(4):742-9. PMID: 6986970.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    526. Krutchik AN, Buzdar AU, Akhtar M, Blumenschein GR. Immune-complex glomerulonephritis secondary to nonspecific immunotherapy. Cancer. 1980 Feb; 45(3):495-7. PMID: 6444365.
      Citations:    Fields:    Translation:HumansCells
    527. Gehan EA, Smith TL, Buzdar AU. Use of prognostic factors in analysis of historical control studies. Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):373-9. PMID: 7407774.
      Citations:    Fields:    Translation:Humans
    528. Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR. Pulmonary toxicity of mitomycin. Cancer. 1980 Jan 15; 45(2):236-44. PMID: 7351010.
      Citations: 5     Fields:    Translation:Humans
    529. Hortobagyi GN, Yap HY, Wiseman CL, Blumenschein GR, Buzdar AU, Legha SS, Gutterman JU, Hersh EM, Bodey GP. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep. 1980 Jan; 64(1):157-9. PMID: 6991103.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    530. Gehan EA, Smith TL, Buzdar AU, Keating MJ, Freireich EJ. Knowledge acquisition from historical data: application to breast cancer patients. Bull Cancer. 1980; 67(4):437-45. PMID: 7013864.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    531. Yap HY, Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Krutchik AN, Benjamin RS, Gutterman JU, Bodey GP. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. J Surg Oncol. 1979 Dec; 12(4):333-41. PMID: 392197.
      Citations:    Fields:    Translation:Humans
    532. Krutchik AN, Buzdar AU. Pigmentation of the tongue and mucous membranes associated with cancer chemotherapy. South Med J. 1979 Dec; 72(12):1615-6. PMID: 515781.
      Citations: 1     Fields:    Translation:Humans
    533. Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med. 1979 Dec; 91(6):847-52. PMID: 517883.
      Citations: 16     Fields:    Translation:Humans
    534. Legha SS, Buzdar AU, Hortobagyi GN, DiStefano A, Wiseman CL, Yap HY, Blumenschein GR, Bodey GP. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2053-6. PMID: 118805.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    535. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Nov; 44(5):1955-62. PMID: 387212.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    536. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Bodey GP. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1961-4. PMID: 526929.
      Citations: 7     Fields:    Translation:Humans
    537. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979 Oct 05; 242(14):1509-13. PMID: 470088.
      Citations: 11     Fields:    Translation:Humans
    538. DiStefano AD, Buzdar AU. Viral-induced remission in chronic lymphocytic leukemia? Arch Intern Med. 1979 Aug; 139(8):946. PMID: 464718.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    539. Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer. 1979 Aug; 44(2):398-405. PMID: 383255.
      Citations: 4     Fields:    Translation:Humans
    540. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 06; 242(1):49-52. PMID: 448865.
      Citations: 6     Fields:    Translation:Humans
    541. Yap HY, Blumenschein GR, Tashima CK, Hortobagyi GN, Buzdar AU, Wiseman CL. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer. 1979 Jul; 44(1):32-4. PMID: 222433.
      Citations: 1     Fields:    Translation:Humans
    542. Buzdar AU, Legha SS, Hortobagyi GN, Blumenschein GR. Drug-associated cardiotoxicity. JAMA. 1979 May 04; 241(18):1893. PMID: 430767.
      Citations:    Fields:    Translation:Humans
    543. Legha SS, Blumenschien GR, Buzdar AU, Hortobagyi GN. Hormone receptors in breast cancer and response to chemotherapy. N Engl J Med. 1979 May 03; 300(18):1053. PMID: 431601.
      Citations:    Fields:    Translation:Humans
    544. Hortobagyi GN, DiStefano A, Legha SS, Buzdar AU, Blumenschein GR. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep. 1979 Apr; 63(4):539-41. PMID: 221118.
      Citations:    Fields:    Translation:Humans
    545. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Apr; 43(4):1225-33. PMID: 445325.
      Citations: 7     Fields:    Translation:Humans
    546. Hortobagyi GN, Gutterman JU, Blumenschein GR, Yap HY, Buzdar AU, Tashima CK, Burgess MA, Hersh EM. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer. 1979 Mar; 43(3):1112-22. PMID: 427716.
      Citations: 3     Fields:    Translation:Humans
    547. Ali MK, Soto A, Maroongroge D, Bekheit-Saad S, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Wiseman CL, Shullenberger CC. Electrocardiographic changes after adriamycin chemotherapy. Cancer. 1979 Feb; 43(2):465-71. PMID: 421174.
      Citations: 6     Fields:    Translation:Humans
    548. Legha SS, Benjamin RS, Buzdar AU, Hortobagyi GN, Blumenschein GR. Rubidazone in metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):135-6. PMID: 369685.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    549. Yap HY, Benjamin RS, Blumenschein GR, Hortobagyi GN, Tashima CK, Buzdar AU, Bodey GP. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):77-83. PMID: 369695.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    550. Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU, Yap HY, Hersh EM. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 1979; 11(4):325-32. PMID: 109703.
      Citations: 5     Fields:    Translation:Humans
    551. Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):115-20. PMID: 369682.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    552. Buzdar AU, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY, Gutterman JU, Hersh EM, Gehan EA. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol. 1979; 12(1):27-40. PMID: 480951.
      Citations: 3     Fields:    Translation:Humans
    553. Krutchik AN, Buzdar AU, Tashima CK. Cyclophosphamide-induced urticaria. Occurrence in a patient with no cross-sensitivity to chlorambucil. Arch Intern Med. 1978 Nov; 138(11):1725-6. PMID: 718329.
      Citations: 1     Fields:    Translation:Humans
    554. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Gu?rin. Cancer Treat Rep. 1978 Nov; 62(11):1685-92. PMID: 728894.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    555. Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM. Spontaneous regression of breast carcinoma. Arch Intern Med. 1978 Nov; 138(11):1734-5. PMID: 718333.
      Citations: 1     Fields:    Translation:Humans
    556. Krutchik AN, Buzdar AU, Blumenschein GR, Sinkovics JG. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. Cancer Treat Rep. 1978 Oct; 62(10):1565-7. PMID: 709557.
      Citations: 1     Fields:    Translation:Humans
    557. Krutchik AN, Buzdar AV. Liver scanning in patients with breast cancer. Arch Surg. 1978 Sep; 113(9):1110-1. PMID: 687115.
      Citations:    Fields:    Translation:Humans
    558. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80. PMID: 706354; PMCID: PMC1238308.
      Citations: 4     Fields:    Translation:Humans
    559. Krutchik AN, Buzdar A, Tashima CK, Blumenschein GR. Endobronchial metastasis from cancer of the breast. Chest. 1978 Sep; 74(3):319-20. PMID: 688798.
      Citations: 1     Fields:    Translation:Humans
    560. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. Arch Intern Med. 1978 Aug; 138(8):1302-3. PMID: 677992.
      Citations:    Fields:    Translation:Humans
    561. Buzdar AU, Legha SS, Tashima CK, Hortobagyi GN, Yap HY, Krutchik AN, Luna MA, Blumenschein GR. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep. 1978 Jul; 62(7):1005-8. PMID: 688243.
      Citations: 13     Fields:    Translation:Humans
    562. Krutchik AN, Buzdar AU. Hepatic metastasis or granuloma. Ann Intern Med. 1978 Jun; 88(6):844-5. PMID: 666149.
      Citations:    Fields:    Translation:Humans
    563. Samaan NA, deAsis DN, Buzdar AU, Blumenschein GR. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 1978 Jun; 41(6):2084-7. PMID: 418867.
      Citations: 7     Fields:    Translation:Humans
    564. Waterfield WC, Tashima CK, Hortobagyi GN, Blumenschein GR, Buzdar AU, Burgess MA. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer. 1978 Apr; 41(4):1235-9. PMID: 638989.
      Citations: 2     Fields:    Translation:Humans
    565. Krutchik AN, Blumenschein GR, Tashima CK, Buzdar AU. Cerebromedullospinal disconnection after intraventricular methotrexate. South Med J. 1978 Apr; 71(4):476-7. PMID: 635633.
      Citations:    Fields:    Translation:Humans
    566. Yap HY, Salem P, Hortobagyi GN, Bodey GP, Buzdar AU, Tashima CK, Blumenschein GR. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep. 1978 Mar; 62(3):405-8. PMID: 348308.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    567. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer. 1978 Mar; 41(3):1064-75. PMID: 638948.
      Citations: 5     Fields:    Translation:Humans
    568. Buzdar AU, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, Bodey GP, Livingston RB. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1978 Feb; 41(2):392-5. PMID: 630529.
      Citations: 3     Fields:    Translation:Humans
    569. Krutchik AN, Buzdar AU, Tashima CK. Azathioprine and breast carcinoma. JAMA. 1978 Jan 09; 239(2):107-8. PMID: 579366.
      Citations: 1     Fields:    Translation:Humans
    570. Buzdar AV, Gutterman JU, Blumenschein GR, Tashima CK, Yap HY, Hersh EM, Gehan EA, Hortob?gyi GN. Adjuvant therapy of stage II, III breast cancer. Recent Results Cancer Res. 1978; 68:123-8. PMID: 379930.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    571. Buzdar A, Eckles NE, Tashima CK. Estrogen therapy and metastatic breast cancer. JAMA. 1977 Jun 27; 237(26):2812. PMID: 577240.
      Citations:    Fields:    Translation:Humans
    572. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar A, Burgess MA, Richman SP, Tashima CK, Schwarz M, Hersh EM. Chemo immunotherapy of advanced breast cancer with BCG. Recent Results Cancer Res. 1977; (62):143-50. PMID: 601328.
      Citations: 1     Fields:    Translation:Humans
    573. In Reply. Archives of Internal Medicine. 145:575.
    574. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Research and Treatment. 161:363-373.
    575. Unilateral lymphangitic carcinomatosis in breast cancer. Revista del Instituto Nacional de Cancerologia. 34:582-584.
    576. Trastuzumab in the treatment of early-stage breast cancer. Breast Diseases. 17:19-22.
    577. Non-invasive cardiac studies before and after adriamycin-containing adjuvant chemotherapy (FAC) for stages II and III breast cancer.
    578. An intensive new adjuvant chemoimmunotherapy program containing 5 fluorouracil (5 FU), adriamycin (AD), cyclophosphamide (CYT), and BCG (FAC BCG) for operable breast cancer.
    579. Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women. Breast Cancer Research and Treatment. 69:290.
    580. Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer.
    581. A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer. International Journal of Experimental and Clinical Chemotherapy. 1:48-55.
    582. In reply [14]. Journal of Clinical Oncology. 23:8131-8132.
    583. Pregnancy and breast cancer. Oncology. 19:697-700.
    584. Regional consolidative therapy following systemic chemotherapy in metastatic breast cancer.
    585. Subclinical Hepatic Toxicity During Combination Chemotherapy for Breast Cancer. JAMA - Journal of the American Medical Association. 256:2988-2990.
    586. Peptichemio in treatment of advanced refractory breast cancer - A phase II study.
    587. Reutilization of doxorubicin in patients with progressive metastatic breast cancer. International Journal of Experimental and Clinical Chemotherapy. 2:234-238.
    588. Adjuvant chemoimmunotherapy of operable breast cancer - Update report.
    589. Anastrozole. Drugs. 62:2491-2492.
    590. Commentary. Annals of Internal Medicine. 159.
    591. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology. 26:1280-1291.
    592. Breast Cancer. 47-61.
    593. Thep McCarthy/Swain article reviewed. Oncology. 14.
    594. Erratum. Cancer. 85:1010.
    595. Locally advanced breast cancer. Oncologist. 1:8-17.
    596. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. Breast Diseases. 16:284-285.
    597. Letter to our readers. American Journal of Hematology/ Oncology. 6:172-173.
    598. Effect of timing of initiation of adjuvant chemotherapy on disease-free (D-F) interval in operable breast cancer. Breast Cancer Research and Treatment. 1.
    599. Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer - An update.
    600. Is breast cancer survival improving?. Breast Diseases. 15:243-244.
    601. Hormonal aspects of breast cancer. Seminars in Breast Disease. 3:61.
    602. Second-line chemotherapy for metastatic breast cancer including quality of life issues. Breast. 5:312-317.
    603. Breast cancer. 19-34.
    604. Recent developments and new directions in adjuvant therapy for breast cancer. Cancer Bulletin. 45:523-527.
    605. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 99:32-38.
    606. Inflammatory breast cancer. Breast Journal. 2:345-352.
    607. Serial Plasma Carcinoembryonic Antigen Measurements During Treatment of Metastatic Breast Cancer. JAMA - Journal of the American Medical Association. 249:1881-1886.
    608. Peplomycin in treatment of advanced metastatic breast cancer-A phase II study.
    609. Update on the adjuvant chemoimmunotherapy of stage IV ned breast cancer.
    610. Erratum. Hospital Pharmacy. 32.
    611. 3-56 Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced Breast Cancer. Breast Diseases. 18:302-303.
    612. Brachial plexopathy and porencephaly in a patient with breast cancer. Cancer Bulletin. 46:185-188.
    613. Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple prior chemotherapies and endocrine agents. Breast Journal. 5:176-181.
    614. In reply [18]. Journal of Clinical Oncology. 23:7760-7761.
    615. In reply [4]. Journal of Clinical Oncology. 24:1482.
    616. High dose oral medroxyprogesterone acetate (MPA) for the treatment of metastatic breast cancer (MBC). 582.
    617. The Goss/Tye Article Reviewed. Oncology. 11:1707-1708.
    618. Adjuvant therapy of stage II, III breast cancer. 123-128.
    619. Tamoxifen. JAMA - Journal of the American Medical Association. 242:49-52.
    620. E17. Are aromatase inhibitors superior to tamoxifen after the menopause. European Journal of Cancer, Supplement. 2:54-55.
    621. Prolongation of disease-free and overall survival with the adjuvant FAC-BCG in stage II, III breast cancer.
    622. The Hamilton/Volm article reviewed. Oncology. 15:978-979.
    623. In reply [12]. Journal of Clinical Oncology. 23:6804-6805.
    624. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment. 1-10.
    625. Erratum. Cancer. 107:2314.
    626. Aromatase inhibitors. American Journal of Cancer. 1:93-100.
    627. Endocrine therapy of metastatic breast cancer. Seminars in Breast Disease. 3:100-111.
    628. Evaluation of tamoxifen in chemotherapy resistant metastatic breast cancer.
    629. Leukocyte interferon (IF) induced tumor regression in patients (pts) with breast cancer and B cell neoplasms.
    630. Adjuvant use of anastrozole in breast cancer [2] (multiple letters). Journal of Clinical Oncology. 22:1524-1527.
    631. Letrozole improved disease-free survival in postmenopausal women after tamoxifen treatment for breast cancer. Evidence-based Obstetrics and Gynecology. 6:91-92.
    632. The Seidman article reviewed. Oncology. 20.
    633. Leukocyte interferon induces tumor regression in patients with breast cancer and B cell neoplasms. Journal of Clinical Hematology and Oncology. 9.
    634. Evaluation of patients after primary therapy for early breast cancer. Cancer Bulletin. 45:528-531.
    635. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research. 17.
    636. Remission and survival data of metastatic breast cancer patients (PTS) achieving complete remission (CR) with combination chemoimmunotherapy (CI). Clinical Research. 26.
    637. The Pritchard article reviewed. Oncology. 14:493.
    638. Breast Cancer in Men [3] (multiple letters). Annals of Internal Medicine. 139:305.
    639. A PHASE I-II evaluation of trioxifene mesylate in the treatment of advanced breast cancer.
    640. U.S. experience in neoadjuvant therapy of operable breast cancer. Seminars in Breast Disease. 7:108-112.
    641. Amphotericin B (AmB) and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma.
    642. Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine. JAMA - Journal of the American Medical Association. 242:1509-1513.
    643. Adriamycin and mitomycin-C - possible synergistic cardiotoxicity. Clinical Research. 26.
    644. Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women. Women's Oncology Review. 4:137-138.
    645. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Obstetrical and Gynecological Survey. 45:691-692.
    646. Letrozole in Breast Cancer [1] (multiple letters). New England Journal of Medicine. 350:727-730.
    647. The current state of preoperative (Neoadjuvant) hormonal therapy for breast cancer. Breast Diseases. 15:219-222.
    648. Current status of adjuvant therapy of breast cancer. Cancer Journal. 9:174-176.
    649. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. Breast Diseases. 16:80-81.
    650. Predictors of systemic recurrence and impact of local failure among early stage breast cancer patients treated with breast conserving therapy. Breast Cancer Research and Treatment. 69:227.
    651. Response to induction chemotherapy in black and white patients with locally advanced breast cancer. Breast Journal. 6:242-246.
    652. Breast cancer in the elderly. Cancer Bulletin. 47:212-217.
    653. Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. Journal of Medical Economics. 2:33-43.
    654. Prolongation of disease-free interval and survival with combined chemoimmunotherapy and irradiation of inflammatory breast carcinoma.
    655. Hormonal Therapy for Metastatic Male Breast Cancer. Archives of Internal Medicine. 143:237-240.
    656. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED). The M. D. Anderson experience. Breast Disease. 7:7-20.
    657. In Reply. JAMA - Journal of the American Medical Association. 260:3129.
    658. Mitomycin-C and megestrol acetate - an active secondline regimen for breast cancer patients refractory to previous treatment.
    659. 10-year analysis of the ATAC trial. The Lancet Oncology. 12:217.
    660. Phase I evaluation of nafazatrom.
    661. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) in stage II or III breast cancer; 5-year results. 571.
    662. Pituitary ovarian function in patients with amenorrhea, during adjuvant chemoimmunotherapy for breast cancer. Clinical Research. 25.
    663. Advances in endocrine therapy for early and advanced breast cancer. 165-172.
    664. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Seminars in Oncology. 24.
    665. Adjuvant chemotherapy for breast cancer with fluorouracil, adriamycin, cyclophosphamide (FAC) with or without BCG and with or without post-operative irradiation (XRT). A prospective randomized study. 557.
    BUZDAR's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (755)
    Explore
    _
    Co-Authors (108)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _